NCT01547221

Brief Summary

Otomycosis is a superficial fungal infection of the external ear canal. Patients should be treated with cleaning fungal debris combined with topical antifungal agent. There is wide range of topical antifungal agents. However, there is still no consensus of the most effective topical antifungal agents in treatment otomycosis is still lacking. According to Thai National List of essential medicines for topical antifugal agents are:

  • acetic acid (2% in aqueous and 2% in 70% isopropyl alcohol)
  • boric acid (3% in isopropyl alcohol)
  • gentian violet
  • clotrimazole ear drop. But from literature review, there is no comparative study between boric acid and clotrimazole solution before. Objective is to compare the clinical effectiveness and adverse events of 1% clotrimazole solution versus 3% boric acid in 70% alcohol for the treatment of otomycosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 22, 2012

Completed
8 days until next milestone

Study Start

First participant enrolled

March 1, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 7, 2012

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

April 28, 2015

Status Verified

April 1, 2015

Enrollment Period

3.1 years

First QC Date

February 22, 2012

Last Update Submit

April 27, 2015

Conditions

Keywords

otomycosis3% boric acid1% clotrimazole ear drop

Outcome Measures

Primary Outcomes (1)

  • result as cure rate of otomycosis

    otolaryngologist's microscopic finding

    1 week after treatment

Secondary Outcomes (1)

  • adverse effect of treatment

    Five minutes after apply treatment

Study Arms (2)

3% boric acid

ACTIVE COMPARATOR

control

Drug: 3% Boric acid

1% clotrimazole ear drop

EXPERIMENTAL

3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.

Drug: clotrimazole

Interventions

single application of 1%clotrimazole ear drop

Also known as: Candid
1% clotrimazole ear drop

3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital

3% boric acid

Eligibility Criteria

Age7 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Symptomatic otomycosis, age more than 7 year.
  • Microscopic finding revealed fungus
  • KOH smear positive for fungus

You may not qualify if:

  • Pregnancy
  • Tympanic membrane perforation and post mastoid surgery
  • Co-infection of ear e.g. severe otitis externa, severe myringitis which are needed other medications
  • Previous using topical antibiotic / steroid within 2weeks.
  • During usage of systemic antifungal drug
  • Allergic to 3% boric acid in70% alcohol or 1% clotrimazole solution.
  • Those who can not come to follow up after one week of the treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ENT clinic KhonKaen Hospital

KhonKaen, KhonKaen, 40000, Thailand

Location

MeSH Terms

Conditions

Otomycosis

Interventions

Clotrimazoleboric acid

Condition Hierarchy (Ancestors)

MycosesBacterial Infections and MycosesInfectionsEar DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Sarisa Romsaithong, M.D.

    Unaffiliate

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical physician, senior professional level

Study Record Dates

First Submitted

February 22, 2012

First Posted

March 7, 2012

Study Start

March 1, 2012

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

April 28, 2015

Record last verified: 2015-04

Locations